NeuroBo Pharma: DMC Recommends Continuation Of Phase 2/3 Trial Of ANA001 Without Modification

NeuroBo Pharmaceuticals, Inc. (NRBO) announced Data Monitoring Committee's recommendation to continue enrollment of the phase 2/3 clinical trial, without modification, for lead drug candidate, ANA001, as a potential treatment for COVID-19. The company plans to complete the phase 2 portion of the trial in the fourth quarter of the current year and to achieve a number of value-creating milestones with this program in the coming months, including initiation of the phase 3 of trial.

The phase 2 part of the trial is anticipated to enroll 60 patients and the primary objective is to assess safety and tolerability. The phase 3 is expected to enroll several hundred patients, with the primary endpoints being median time to hospital discharge, safety and tolerability.

Shares of NeuroBo Pharmaceuticals were up 19% in pre-market trade on Wednesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT